NEW YORK (GenomeWeb News) — Protein therapy products maker GenOdyssee today said it will provide Baxter with its technology, intellectual property, and integrated processes.
 
Under the agreement, Baxter will use these platforms to discover "novel blood clotting factors" in the course of its hemophilia research, and will develop and market any "commercially viable products" resulting from the partnership.
 
Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.